0 0.0141509433962265 0.00174528301886805 0.0141509433962265 4.71698113208543E-05 0.00504716981132072 0.0141509433962265 0.00490566037735858
Sign Up Today X
Thanks for submitting the form.
Stockreport

Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma, with several investment banks added as co-lead underwriters. The interim ALPHA3 data showed that more than half of MRD-positive patients receiving cema-cel achieved molecular residual disease clearance, with substantial reductions in plasma ctDNA compared with observation, highlighting a potential role for off-the-shelf allogeneic CAR T therapy in an earlier treatment setting guided by MRD testing. Next, we will examine how this early MRD clearance signal from ALPHA3 could reshape Allogene's pre-existing investment narrative and risk profile. Uncover the next big thing with 31 elite penny stocks that balance risk and reward. Allogene Therapeutics Investment Narrative Recap To own Allogene here, you have to believe cema cel can turn early MRD clearance in ALPHA3 into a viable first line consolidation option while the company finances itself through piv [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma, with several investment banks added as co-lead underwriters. The interim ALPHA3 data showed that more than half of MRD-positive patients receiving cema-cel achieved molecular residual disease clearance, with substantial reductions in plasma ctDNA compared with observation, highlighting a potential role for off-the-shelf allogeneic CAR T therapy in an earlier treatment setting guided by MRD testing. Next, we will examine how this early MRD clearance signal from ALPHA3 could reshape Allogene's pre-existing investment narrative and risk profile. Uncover the next big thing with 31 elite penny stocks that balance risk and reward. Allogene Therapeutics Investment Narrative Recap To own Allogene here, you have to believe cema cel can turn early MRD clearance in ALPHA3 into a viable first line consolidation option while the company finances itself through piv [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS